To date, no combinatorial studies of SHP-1 inhibition together with PD-1 or CTLA-4 inhibition have been conducted, however, the studies discussed above, in particular the work by Hebeisen et al. [28], suggest that such combinations are more likely to be synergistic than redundant in their anti-tumour effects. The gene discussed is PTPN6; the disease is neoplasm.